Wall Street is positive on Oramed Pharmaceuticals, Inc. (ORMP). On average, analysts give Oramed Pharmaceuticals, Inc. a Hold rating. The average price target is $3.65, which means analysts expect the stock to climb by 8.31% over the next twelve months. That average ranking earns Oramed Pharmaceuticals, Inc. an Analyst Rating of 5, which is better than 5% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating ORMP a Hold today. Find out what this means to you and get the rest of the rankings on ORMP!